Among 10,977 NHANES participants, both lower and higher EGCG intake categories, relative to non-consumers, were associated with reduced PhenoAge acceleration, lower all-cause mortality, and longer estimated residual life expectancy. In C. elegans, EGCG extended lifespan and healthspan by upregulating peroxisome biogenesis genes (prx-5, prx-19) and peroxisomal fatty acid β-oxidation enzymes (acox-1.2, acox-3, dhs-28), lowering very long-chain fatty acids. Knocking down these genes erased the benefit. In doxorubicin-senescent mouse hepatocytes, EGCG cut SA-β-gal positivity and p16/p21, again dependent on Pex5 and Acox1.
The human and mechanistic halves of this paper carry very different weight. The NHANES signal is observational: tea drinkers differ from non-drinkers in income, education, smoking, and overall diet, and a dietary recall of EGCG at one time point is a crude exposure measure. Notably, the non-linear pattern, with both low and high intake looking similar, hints at residual confounding rather than a clean dose-response. The mechanism comes entirely from worms and cultured cells, and EGCG doses used in worm studies often far exceed what a cup of green tea delivers; the human relevance of peroxisomal β-oxidation as the operative pathway remains unproven. Peroxisome decline with age is a credible, underexplored aging axis, which makes this the more interesting contribution. Still, this is incremental: it echoes decades of tea-and-mortality cohort data and adds a plausible mechanism, not proof. Drinking green tea is low-risk and reasonable, but this work does not justify high-dose EGCG supplements, which carry documented liver-toxicity risk.